Hematological malignancies
Drug research and approvals for hematological malignancies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 471 studies of hematological malignancies are recruiting on ClinicalTrials.gov, and Health Canada has authorized 33 drug trials for it since 2013.
- Recruiting worldwide: 471
- Trials authorized in Canada: 33
- FDA orphan approvals: 0
- EU medicines: 0
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- A Personalised Anti-fatigue Program for Community-dwelling People With Chronic Lymphocytic LeukaemiaNCT07940920 · Not applicable · University of Surrey · starts Dec 1, 2026
- Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCyNCT07940738 · Phase 1 · H. Lee Moffitt Cancer Center and Research Institute · starts Dec 1, 2026
- Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor BoardsNCT07939139 · Not reported · Technical University of Munich · starts Nov 9, 2026
- High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting…NCT07926217 · Phase 2 · Sung-Han Kim · starts Nov 2, 2026
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersNCT07914556 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Sep 16, 2026
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic…NCT07912684 · Not applicable · Gruppo Italiano Malattie EMatologiche dell'Adulto · starts Nov 10, 2026
- Middle East Study of Infections in Patients With Hematological MalignanciesNCT07900542 · Not reported · Hamad Medical Corporation · starts Sep 15, 2024
- Comprehensive Palliative Care After Stem Cell Transplantation: a Feasability StudyNCT07895693 · Not applicable · Lisa Hentsch · starts Aug 27, 2026
How its trials ended
1,259 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 275 whose ending is known, 33% met their primary endpoint, 1% missed it and 65% stopped early.
- Completed, result not reported42834%
- Ongoing40732%
- Status unknown14912%
- Stopped: other or unclear947%
- Met its primary endpoint927%
- Stopped: enrollment or feasibility423%
- Stopped: sponsor or business decision232%
- Stopped: lack of efficacy151%
- Missed its primary endpoint4<1%
- Stopped: safety3<1%
- Stopped: funding2<1%
| Nov 13, 2026 | Dualis: a modular phase I/II, open-label, multicentre study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and…AZD1221 | AstraZeneca Pharmaceuticals | Pending |
| Jul 15, 2026 | A phase 3, prospective, open-label, multicenter, single-arm study to investigate the efficacy, safety, and pharmacokinetics of IGPRO20 in subjects with…Hizentra | CSL | Pending |
| Aug 15, 2024 | Lightbeam-U01 substudy 01a: a phase 1/2 substudy to evaluate the safety and efficacy of zilovertamab vedotin in pediatric and young adult participants with…Zilovertamab vedotin (MK-2140) / Patritumab deruxtecan / Ifinatamab deruxtecan | Merck & Co. (MSD) | Ongoing |
| May 3, 2024 | Cold versus room temperature storage of platelets for bleeding in hematologic malignancy a pilot trial (coverts-hm)Apheresis platelets psoralen treated / Pooled platelets psoralen treated | Ottawa Hospital Research Institute | Pending |
| Aug 22, 2023 | An open-label, multicenter, roll-over study for patients who have completed a prior novartis-sponsored sabatolimab (MBG453) study and are judged by the…MBG453 | Novartis Pharmaceuticals | Ongoing |
| Apr 26, 2023 | A phase 1 open-label, multi-center, safety and efficacy study of PRT2527 as monotherapy and in combination with zanubrutinib or venetoclax in participants with…PRT2527 / Zanubrutinib/ Venetoclax | Prelude Therapeutics | Closed |
| Apr 13, 2023 | Phase 1/2 study of 9-ING-41, a glycogen synthase KINASE-3 beta (GSK-3B) inhibitor, as a single agent and combined with chemotherapy, in patients with…Elraglusib (9-ING-41) | Actuate Therapeutics | Ongoing |
| Aug 6, 2021 | A phase 2, open-label study to evaluate the safety and efficacy of mk- 7684a (MK-7684 [vibostolimab] with MK-3475 [pembrolizumab] coformulation) in…MK-7684A (vibostolimab + pembrolizumab) | Merck & Co. (MSD) | Ongoing |
| Jul 9, 2021 | Infusion of ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, for refractory/recurring infection or disease…ATIR101 | Hopital Maisonneuve Rosemont | Pending |
| Feb 4, 2021 | A phase 2 study to evaluate the efficacy and safety of MK-1026 in participants with hematologic malignanciesNemtabrutinib (MK-1026) | Merck & Co. (MSD) | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA